ArticleWorld journal of surgical oncology2026
Comparative analysis of clinicopathological characteristics and prognosis between E-cadherin-negative breast lymphoepithelioma-like carcinoma and E-cadherin-negative invasive lobular carcinoma.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundE-cadherin-negative breast lymphoepithelial-like carcinoma (E-Cad-neg BLEC) is a rare malignant tumor. To date, no study has compared the clinicopathological characteristics and prognosis between E-Cad-neg BLEC and E-Cad-neg invasive lobular carcinoma (ILC).
methodsTo clarify the relationship between E-Cad-neg BLEC and E-Cad-neg ILC, we analyzed 12 patients with E-Cad-neg BLEC, comparing their clinicopathological characteristics and tumor prognosis with those of 578 patients with E-Cad-neg classical invasive lobular carcinoma (c-ILC) or 43 patients with E-Cad-neg pleomorphic lobular carcinoma (PLC).
resultsThe results showed that E-Cad-neg BLEC was a diffuse, non-adherent tumor with pleomorphic growth. There was abundant lymphocyte infiltration in the tumor stroma. Lobular carcinoma in situ was observed around the tumor in 5 patients. Compared with E-Cad-neg c-ILC, E-Cad-neg BLEC had significantly lower expression levels of ER (p < 0.001), PR (p < 0.001), and HER2 (p = 0.029), and a higher Ki-67 proliferation index (p < 0.001). Compared with E-Cad-neg PLC, E-Cad-neg BLEC was less likely to exhibit vascular invasion (p < 0.001) and perineural invasion (p < 0.001), and had lower HER2 expression (p = 0.001). In terms of histo-molecular subtypes, E-Cad-neg BLEC was mainly triple-negative, while E-Cad-neg c-ILC and E-Cad-neg PLC were mainly luminal A and luminal B. Regarding prognosis, the prognosis curve of E-Cad-neg BLEC was close to that of E-Cad-neg c-ILC. Analysis of the percentage of tumor-infiltrating lymphocytes (TILs) revealed that in both E-Cad-neg c-ILC and E-Cad-neg PLC, higher TIL levels were associated with a poor prognosis, in contrast to the favorable prognosis observed in E-Cad-neg BLEC.
conclusionsOur findings indicate that E-Cad-neg BLEC is a type of breast carcinoma characterized by extensive lymphocytic infiltration and high proliferative activity and is associated with a relatively favorable prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.